Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Nathalie Bauer

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5005561235. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2014: 3 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper

Papers 13

  1. Correction: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.28527↗
  2. [Corrigendum] Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer. Co-author DOI 10.3892/ijo.2023.5543↗
  3. [Corrigendum] Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer. Co-author DOI 10.3892/or.2023.8626↗
  4. Dexamethasone-induced inhibition of miR-132 via methylation promotes TGF-β-driven progression of pancreatic cancer. Co-author DOI 10.3892/ijo.2018.4616↗
  5. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.04.001↗
  6. microRNA-210 overexpression inhibits tumor growth and potentially reverses gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.11.035↗
  7. Dexamethasone mediates pancreatic cancer progression by glucocorticoid receptor, TGFβ and JNK/AP-1. Co-author DOI 10.1038/cddis.2017.455↗
  8. MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.01.038↗
  9. Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy. Co-author DOI 10.1038/cddis.2016.157↗
  10. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3171↗
  11. Triptolide reverses hypoxia-induced epithelial-mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Co-author DOI 10.1002/ijc.28583↗
  12. Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine. Co-author DOI 10.18632/oncotarget.2120↗
  13. Establishment of hypoxia induction in an in vivo animal replacement model for experimental evaluation of pancreatic cancer. Co-author DOI 10.3892/or.2014.3196↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ingrid Herr · 13 shared papers, 2014–2024 · strength 1.20
  2. Oliver Strobel · 6 shared papers, 2015–2024 · strength 0.62
  3. Li Liu · 5 shared papers, 2014–2024 · strength 0.60
  4. Clifford C. Nwaeburu · 7 shared papers, 2014–2023 · strength 0.52
  5. Pei Fan · 6 shared papers, 2014–2024 · strength 0.44
  6. Thilo Hackert · 4 shared papers, 2015–2024 · strength 0.36
  7. Yiyao Zhang · 4 shared papers, 2014–2024 · strength 0.31
  8. Alia Abukiwan · 3 shared papers, 2016–2023 · strength 0.31
  9. Alexandr V. Bazhin · 3 shared papers, 2014–2024 · strength 0.26
  10. Li Liu · 2 shared papers, 2019–2023 · strength 0.26
  11. Nathalia A. Giese · 2 shared papers, 2015–2024 · strength 0.23
  12. Eduard Ryschich · 2 shared papers, 2015–2024 · strength 0.23
  13. Franco Fortunato · 2 shared papers, 2015–2024 · strength 0.23
  14. Yefeng Yin · 3 shared papers, 2016–2018 · strength 0.17
  15. Peter Schemmer · 3 shared papers, 2014–2016 · strength 0.14
  16. Prince Saforo Amponsah · 2 shared papers, 2016–2017 · strength 0.13
  17. Li Liu · 2 shared papers, 2014–2017 · strength 0.10
  18. Libo Yin · 1 shared paper, 2018 · strength 0.07
  19. Xi Xiao · 1 shared paper, 2016 · strength 0.05
  20. Jens Werner · 1 shared paper, 2014 · strength 0.04
  21. Orkhan Isayev · 1 shared paper, 2014 · strength 0.03
  22. Felix Rückert · 1 shared paper, 2014 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.